Explore combination strategies that target OCT4 and other key master regulators—such as SOX2, MYC, EZH2, and BRN2—alongside immunotherapies, to more effectively disrupt the stemness and immune-evasive phenotypes associated with lineage plasticity in prostate cancer. This evidence concerns the gene SOX2 and prostate carcinoma.